drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate (ADC)
drug_description
An antibody–drug conjugate targeting folate receptor alpha; a humanized anti-FRα IgG1 linked to the maytansinoid payload DM4 that, after receptor-mediated internalization, releases DM4 to inhibit tubulin polymerization, causing mitotic arrest and apoptosis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
mirvetuximab soravtansine
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
A humanized anti–folate receptor alpha (FRα) IgG1 monoclonal antibody conjugated to the maytansinoid payload DM4; after FRα binding and receptor-mediated internalization, linker cleavage releases DM4 to inhibit tubulin polymerization, disrupting microtubules and inducing mitotic arrest and apoptosis, with potential local bystander effect.
drug_name
TAK-853 (mirvetuximab soravtansine)
nct_id_drug_ref
NCT06390995